Using a blood clotting factor to treat acute brain bleeding quickly
Official title: FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial
Funded at University of Cincinnati · NIH-11014938 · Data updated 2026-11-12
This study is looking at whether giving a special medication called rFVIIa to people who have a sudden brain bleed can help them recover better when it's given quickly, along with regular treatment, and it involves 860 patients from different countries.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | March 1, 2020 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $4,412,639 |
| NIH project number | 5U01NS110772-04 |
| Project ID | NIH-11014938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals aged 80 or younger who have experienced a spontaneous intracerebral hemorrhage and can be treated within two hours of symptom onset.
✕Less likely to help
Patients with larger volumes of hemorrhage or those with significant intraventricular hemorrhage may not benefit from this research.
What this research studies
This research investigates the use of recombinant Factor VIIa (rFVIIa) in patients experiencing acute intracerebral hemorrhage (ICH). The trial aims to determine if administering rFVIIa within two hours of symptom onset, alongside standard treatment, can improve patient outcomes compared to standard treatment alone. The study will involve 860 patients across multiple countries and will utilize mobile stroke units to expedite treatment. Participants will be monitored for their recovery over 90 days using a standardized scale.
Why it matters
Potential benefit: If successful, this research could significantly improve recovery outcomes for patients suffering from acute brain hemorrhages.
How similar studies have gone: Previous studies have shown promising results with similar approaches in treating acute strokes, indicating potential for success in this trial.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Broderick, Joseph Paul — University of Cincinnati
- Study coordinator: Broderick, Joseph Paul
Related research
Other NIH-funded projects on the same topics.
-
Cross-talk between SARM1-driven axon damage and ferroptosis in brain hemorrhage
A study in people with brain bleeding (intracerebral hemorrhage) to understand how axons get damaged and how iron-related cell death contributes to disability.
-
Recombinant factor VIIa given very early for bleeding stroke
This trial gives a clotting medicine called rFVIIa very soon after a spontaneous brain bleed to adults to try to improve recovery.
-
Early Factor VIIa treatment for bleeding stroke
This project tests whether giving a clotting medicine called recombinant Factor VIIa very soon after a spontaneous brain bleed helps adults recover better than standard care alone.
-
Early clotting-factor treatment for sudden brain bleed
This research gives a clotting medicine called rFVIIa very soon after a sudden brain bleed to see whether people with intracerebral hemorrhage do better than with standard care alone.
-
Ultrasound method to safely treat brain bleeds without open surgery
A new ultrasound-based technique aims to liquefy and drain intracerebral hemorrhage through the skull in a minimally invasive way.
-
Early Factor VIIa treatment for bleeding stroke
This research compares early intravenous recombinant Factor VIIa plus usual care with usual care alone for people who have a sudden brain bleed (intracerebral hemorrhage) to try to improve recovery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.